Search
  1. Home
  2. West Africa
  3. Cameroon
  • News

HIV vaccine development tops meeting agenda

    JOHANNESBURG

    Some 200 experts are reviewing the current status of HIV vaccine research and development at a gathering that kicked off on Monday in Yaounde, capital of Cameroon.

    According to the World Health Organisation (WHO), delegates at the three-day forum will also examine a range of challenges concerning Africa's active participation and contribution to the project.

    WHO Regional Director for Africa, Dr. Luis Gomes, said in a statement, "On top of the great scientific challenges that need to be overcome in order to develop an HIV vaccine, Africa is currently facing the need to strengthen capacity in many areas in order to support such research."

    Five African countries are conducting phase I and phase II clinical trials of candidate HIV vaccines, and one large-scale phase III trial involving 16,000 volunteers is underway in Thailand.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join